Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))

Dhivya R Sudhan; Angel Guerrero-Zotano; Helen Won; Paula González Ericsson; Alberto Servetto; Mariela Huerta-Rosario; Dan Ye; Kyung min Lee; Luigi Formisano; Yan Guo; Qi Liu; Lisa N. Kinch; Monica Red Brewer; Teresa Dugger; James Koch; Michael J. Wick; Richard E. Cutler; Alshad S. Lalani; Richard Bryce; Alan Auerbach; Ariella B. Hanker; Carlos L. Arteaga

doi:10.1016/j.ccell.2020.01.010

Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))

Dhivya R Sudhan, Angel Guerrero-Zotano, Helen Won, Paula González Ericsson, Alberto Servetto, Mariela Huerta-Rosario, Dan Ye, Kyung min Lee, Luigi Formisano, Yan Guo, Qi Liu, Lisa N. Kinch, Monica Red Brewer, Teresa Dugger, James Koch, Michael J. Wick, Richard E. Cutler, Alshad S. Lalani, Richard Bryce, Alan AuerbachAriella B. Hanker, Carlos L. Arteaga

Research output: Contribution to journal › Comment/debate › peer-review

9 Scopus citations

Abstract

Main Text (Cancer Cell 37, 183–199.e1–e5; February 10, 2020) In the originally published version of this article, during final figure preparation the authors inadvertently selected an incorrect dose response graph for Figure 1D (bottom row, middle sub-panel; parental versus neratinib-resistant OVCAR8 lapatinib dose response assay). The lapatinib sensitivity graph for 5637 cells from the top row was mistakenly copied into the OVCAR8 panel. The correction to the graph in Figure 1D does not affect the conclusions of the paper. The authors apologize for any confusion or inconvenience that this oversight may have caused.

Original language	English (US)
Pages (from-to)	258-259
Number of pages	2
Journal	Cancer Cell
Volume	37
Issue number	2
DOIs	https://doi.org/10.1016/j.ccell.2020.01.010
State	Published - Feb 10 2020

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ccell.2020.01.010

Fingerprint

Dive into the research topics of 'Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))'. Together they form a unique fingerprint.

Cite this

Sudhan, D. R., Guerrero-Zotano, A., Won, H., Ericsson, P. G., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K. M., Formisano, L., Guo, Y., Liu, Q., Kinch, L. N., Brewer, M. R., Dugger, T., Koch, J., Wick, M. J., Cutler, R. E., Lalani, A. S., Bryce, R., ... Arteaga, C. L. (2020). Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013)). Cancer Cell, 37(2), 258-259. https://doi.org/10.1016/j.ccell.2020.01.010

Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013)). / Sudhan, Dhivya R; Guerrero-Zotano, Angel; Won, Helen et al.
In: Cancer Cell, Vol. 37, No. 2, 10.02.2020, p. 258-259.

Research output: Contribution to journal › Comment/debate › peer-review

Sudhan, DR, Guerrero-Zotano, A, Won, H, Ericsson, PG, Servetto, A, Huerta-Rosario, M, Ye, D, Lee, KM, Formisano, L, Guo, Y, Liu, Q, Kinch, LN, Brewer, MR, Dugger, T, Koch, J, Wick, MJ, Cutler, RE, Lalani, AS, Bryce, R, Auerbach, A, Hanker, AB & Arteaga, CL 2020, 'Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))', Cancer Cell, vol. 37, no. 2, pp. 258-259. https://doi.org/10.1016/j.ccell.2020.01.010

Sudhan DR, Guerrero-Zotano A, Won H, Ericsson PG, Servetto A, Huerta-Rosario M et al. Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013)). Cancer Cell. 2020 Feb 10;37(2):258-259. doi: 10.1016/j.ccell.2020.01.010

@article{c4874ad22da94da0ab57be8b4073279e,

title = "Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))",

abstract = "Main Text (Cancer Cell 37, 183–199.e1–e5; February 10, 2020) In the originally published version of this article, during final figure preparation the authors inadvertently selected an incorrect dose response graph for Figure 1D (bottom row, middle sub-panel; parental versus neratinib-resistant OVCAR8 lapatinib dose response assay). The lapatinib sensitivity graph for 5637 cells from the top row was mistakenly copied into the OVCAR8 panel. The correction to the graph in Figure 1D does not affect the conclusions of the paper. The authors apologize for any confusion or inconvenience that this oversight may have caused.",

author = "Sudhan, {Dhivya R} and Angel Guerrero-Zotano and Helen Won and Ericsson, {Paula Gonz{\'a}lez} and Alberto Servetto and Mariela Huerta-Rosario and Dan Ye and Lee, {Kyung min} and Luigi Formisano and Yan Guo and Qi Liu and Kinch, {Lisa N.} and Brewer, {Monica Red} and Teresa Dugger and James Koch and Wick, {Michael J.} and Cutler, {Richard E.} and Lalani, {Alshad S.} and Richard Bryce and Alan Auerbach and Hanker, {Ariella B.} and Arteaga, {Carlos L.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = feb,

day = "10",

doi = "10.1016/j.ccell.2020.01.010",

language = "English (US)",

volume = "37",

pages = "258--259",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Erratum

T2 - Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))

AU - Sudhan, Dhivya R

AU - Guerrero-Zotano, Angel

AU - Won, Helen

AU - Ericsson, Paula González

AU - Servetto, Alberto

AU - Huerta-Rosario, Mariela

AU - Ye, Dan

AU - Lee, Kyung min

AU - Formisano, Luigi

AU - Guo, Yan

AU - Liu, Qi

AU - Kinch, Lisa N.

AU - Brewer, Monica Red

AU - Dugger, Teresa

AU - Koch, James

AU - Wick, Michael J.

AU - Cutler, Richard E.

AU - Lalani, Alshad S.

AU - Bryce, Richard

AU - Auerbach, Alan

AU - Hanker, Ariella B.

AU - Arteaga, Carlos L.

PY - 2020/2/10

Y1 - 2020/2/10

N2 - Main Text (Cancer Cell 37, 183–199.e1–e5; February 10, 2020) In the originally published version of this article, during final figure preparation the authors inadvertently selected an incorrect dose response graph for Figure 1D (bottom row, middle sub-panel; parental versus neratinib-resistant OVCAR8 lapatinib dose response assay). The lapatinib sensitivity graph for 5637 cells from the top row was mistakenly copied into the OVCAR8 panel. The correction to the graph in Figure 1D does not affect the conclusions of the paper. The authors apologize for any confusion or inconvenience that this oversight may have caused.

AB - Main Text (Cancer Cell 37, 183–199.e1–e5; February 10, 2020) In the originally published version of this article, during final figure preparation the authors inadvertently selected an incorrect dose response graph for Figure 1D (bottom row, middle sub-panel; parental versus neratinib-resistant OVCAR8 lapatinib dose response assay). The lapatinib sensitivity graph for 5637 cells from the top row was mistakenly copied into the OVCAR8 panel. The correction to the graph in Figure 1D does not affect the conclusions of the paper. The authors apologize for any confusion or inconvenience that this oversight may have caused.

UR - http://www.scopus.com/inward/record.url?scp=85078933289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85078933289&partnerID=8YFLogxK

U2 - 10.1016/j.ccell.2020.01.010

DO - 10.1016/j.ccell.2020.01.010

M3 - Comment/debate

C2 - 32049049

AN - SCOPUS:85078933289

SN - 1535-6108

VL - 37

SP - 258

EP - 259

JO - Cancer Cell

JF - Cancer Cell

IS - 2

ER -

Erratum: Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers (Cancer Cell (2020) 37(2) (183–199.e5), (S1535610819305835), (10.1016/j.ccell.2019.12.013))

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this